AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Amgen's $14.30 Billion Trading Day Sees 40th Ranking Amidst Stock Decline
Generated by AI AgentAinvest Volume Radar
Monday, Jun 23, 2025 8:00 pm ET1min read
On June 23, 2025, Amgen's trading volume reached $14.30 billion, a 27.53% decrease from the previous day, ranking 40th in the day's stock market. Amgen's stock price fell by 5.83%, marking the fourth consecutive day of decline, with a total decrease of 7.82% over the past four days.
Amgen's Phase 2 obesity study demonstrated significant results with its drug MariTide, showing an average weight loss of approximately 20% in individuals with obesity who do not have Type 2 diabetes. This finding is particularly noteworthy as it indicates the potential for further weight loss beyond the 52-week trial period.
However, the study also revealed a high rate of side effects and discontinuations, which could impact the drug's marketability and patient adherence. Despite these challenges,
is expanding its development plans for MariTide, aiming to study its use for heart disease and sleep apnea.The company plans to initiate a third phase of trials lasting 72 weeks to evaluate the safety, efficacy, and tolerability of MariTide for overweight and obese patients with and without Type 2 diabetes. Additionally, Amgen expects to start Phase 3 studies for atherosclerotic cardiovascular disease, heart failure, and obstructive sleep apnea in 2025.
Ainvest Volume Radar
Hunt down the stocks with explosive trading volume.
Latest Articles
Kraft Heinz Slides 1.02% as Stock Ranks 486th in Daily Trading Volume Amid Institutional Splits Earnings Woes and Dividend Strain Weigh on Investor Confidence
Dec.05 2025
AVAV's 3.15% Slide Amid 21% Volume Drop, 475th Rank Signal Earnings Optimism Fizzles
Dec.05 2025
Align Technology Extends Three-Day Rally with 0.24 Gain Ranks 452nd in $250M Turnover as Dental Sector Outperforms Peers
Dec.05 2025
PPG's 0.36% Rise Outpaces 448th-Ranked Volume as Analysts Boost Aerospace Growth Outlook
Dec.05 2025
Akamai's FedRAMP Certification Drives 31.33% Volume Surge to 445th Rank, but Stock Dips 3.59% on Investor Caution
Dec.05 2025
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet